Point72 Asia Singapore Pte. Ltd. Buys New Position in Vor Biopharma Inc. (NYSE:VOR)

Point72 Asia Singapore Pte. Ltd. bought a new position in Vor Biopharma Inc. (NYSE:VOR) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 63,262 shares of the company’s stock, valued at approximately $63,000. Point72 Asia Singapore Pte. Ltd. owned 0.09% of Vor Biopharma at the end of the most recent quarter.

Several other large investors have also bought and sold shares of VOR. Hsbc Holdings PLC boosted its position in shares of Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Vor Biopharma in the 2nd quarter worth about $53,000. Acadian Asset Management LLC bought a new position in shares of Vor Biopharma in the 1st quarter worth about $126,000. Renaissance Technologies LLC lifted its position in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after acquiring an additional 160,642 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after acquiring an additional 69,436 shares in the last quarter. 97.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on VOR. HC Wainwright reaffirmed a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a research note on Friday, September 6th. JMP Securities reiterated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, Barclays dropped their target price on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $10.92.

Vor Biopharma Stock Down 3.5 %

NYSE:VOR opened at $0.71 on Monday. Vor Biopharma Inc. has a 52 week low of $0.69 and a 52 week high of $3.14. The stock has a market cap of $48.40 million, a price-to-earnings ratio of -0.40 and a beta of -0.34. The company’s 50 day moving average price is $0.91 and its 200-day moving average price is $1.33.

Vor Biopharma (NYSE:VOR) last issued its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.41). As a group, sell-side analysts anticipate that Vor Biopharma Inc. will post -1.51 earnings per share for the current year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.